Stock IDYA IDEAYA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
39.94 USD +3.42% Intraday chart for IDEAYA Biosciences, Inc. +7.57% +12.25%
04-22 IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy MT
04-22 IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer CI

Business Summary

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Number of employees: 124

Sales per Business

USD in Million2022Weight2023Weight Delta
Oncology-focused Precision Medicine
100.0 %
51 100.0 % 23 100.0 % -54.08%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
51 100.0 % 23 100.0 % -54.08%

Managers

Managers TitleAgeSince
Yujiro Hata FOU
 Founder 49 31/05/15
Andres Briseno DFI
 Director of Finance/CFO 38 31/07/16
Michael White CTO
 Chief Tech/Sci/R&D Officer - 31/10/21
Paul A. Barsanti CTO
 Chief Tech/Sci/R&D Officer - 30/06/19
Darrin Beaupre CTO
 Chief Tech/Sci/R&D Officer - 20/11/22
Mick O'Quigley PRN
 Corporate Officer/Principal - 31/12/17
Jason Throne LAW
 General Counsel 53 30/09/19

Members of the board

Members of the board TitleAgeSince
Terry Rosen BRD
 Director/Board Member 64 05/05/16
Wendy Yarno BRD
 Director/Board Member 68 16/12/19
Catherine Mackey BRD
 Director/Board Member 68 04/04/22
Yujiro Hata FOU
 Founder 49 31/05/15
Jeffrey Stein BRD
 Director/Board Member 69 30/09/15
Susan Kelley BRD
 Director/Board Member 69 16/02/21
Garret Hampton BRD
 Director/Board Member 58 25/06/20
Scott Morrison BRD
 Director/Board Member 66 30/06/18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,764,628 74,032,280 ( 99.02 %) 0 99.02 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
6.862 %
5,116,525 6.862 % 225 M $
Federated MDTA LLC
5.209 %
3,883,775 5.209 % 170 M $
T. Rowe Price International Ltd.
4.783 %
3,566,278 4.783 % 156 M $
Janus Henderson Investors US LLC
4.764 %
3,551,891 4.764 % 156 M $
Vanguard Fiduciary Trust Co.
4.662 %
3,475,772 4.662 % 153 M $
STATE STREET CORPORATION
4.013 %
2,991,899 4.013 % 131 M $
Adage Capital Partners GP LLC
3.923 %
2,925,094 3.923 % 128 M $
Deerfield Management Co. LP (Private Equity)
3.528 %
2,630,292 3.528 % 115 M $
Boxer Capital LLC
2.954 %
2,202,812 2.954 % 97 M $
Capital Research & Management Co. (Global Investors)
2.651 %
1,976,870 2.651 % 87 M $

Company contact information

IDEAYA Biosciences, Inc.

7000 Shoreline Court Suite 350

94080-1945, South San Francisco

+650 443 6209

http://www.ideayabio.com
address IDEAYA Biosciences, Inc.(IDYA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for IDEAYA Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
39.94 USD
Average target price
53.5 USD
Spread / Average Target
+33.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IDEAYA BIOSCIENCES, INC. Stock IDEAYA Biosciences, Inc.
+12.25% 2.99B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IDYA Stock
  4. Company IDEAYA Biosciences, Inc.